key: cord-1030854-pjuoje7p
authors: Wiegand, Steffen B.; Traeger, Lisa; Nguyen, Huan K.; Rouillard, Kaitlyn R.; Fischbach, Anna; Zadek, Francesco; Ichinose, Fumito; Schoenfisch, Mark H.; Carroll, Ryan W.; Bloch, Donald B.; Zapol, Warren M.
title: Antimicrobial effects of nitric oxide in murine models of Klebsiella pneumonia
date: 2020-12-11
journal: Redox Biol
DOI: 10.1016/j.redox.2020.101826
sha: 3e1112e902aef84ba16103fb77c9b6a6f0488a65
doc_id: 1030854
cord_uid: pjuoje7p

RATIONALE: Inhalation of nitric oxide (NO) exerts selective pulmonary vasodilation. Nitric oxide also has an antimicrobial effect on a broad spectrum of pathogenic viruses, bacteria and fungi. OBJECTIVES: The aim of this study was to investigate the effect of inhaled NO on bacterial burden and disease outcome in a murine model of Klebsiella pneumonia. METHODS: Mice were infected with Klebsiella pneumoniae and inhaled either air alone, air mixed with constant levels of NO (at 80, 160, or 200 parts per million (ppm)) or air intermittently mixed with high dose NO (300 ppm). Forty-eight hours after airway inoculation, the number of viable bacteria in lung, spleen and blood was determined. The extent of infiltration of the lungs by inflammatory cells and the level of myeloperoxidase activity in the lungs were measured. Atomic force microscopy was used to investigate a possible mechanism by which nitric oxide exerts a bactericidal effect. MEASUREMENTS AND MAIN RESULTS: Compared to control animals infected with K. pneumoniae and breathed air alone, intermittent breathing of NO (300ppm) reduced viable bacterial counts in lung and spleen tissue. Inhaled NO reduced infection-induced lung inflammation and improved overall survival of mice. NO destroyed the cell wall of K. pneumoniae and killed multiple-drug resistant K. pneumoniae in-vitro. CONCLUSIONS: Intermittent administration of high dose NO may be an effective approach to the treatment of pneumonia caused by K. pneumoniae.

Nitric oxide (NO) plays a pivotal role in the regulation of vascular tone, neurotransmission, acute and chronic inflammation, and host defense [1, 2] . Low dose NO (up to 80ppm) is a selective pulmonary vasodilator, approved by the FDA in December 1999 which has been used in over 300,000 babies with persistent pulmonary hypertension of the newborn and for adults to treat pulmonary hypertension and right ventricular failure [3] [4] [5] [6] .

NO has an antimicrobial effect against a broad range of pathogenic organisms, including viruses (such as SARS-CoV-1, SARS-CoV-2), bacteria and fungi [2, 7, 8] . At low concentrations (<1µM), NO functions in intercellular signal transduction [9] . At higher concentrations, NO increases the level of reactive nitrogen species (RNS) [10] . Putative mechanisms of the bactericidal effects of NO and RNOS include nitrosation of cysteine thiols (e.g. in bacterial cells [11] ), disruption of iron-sulfur clusters in the respiratory chain of bacteria [12] , inhibition of ribonucleotide reductase, an enzyme needed for repairing bacterial DNA [13] , and downregulation of ferroportin, the exporter of cellular iron, which is needed for bacterial metabolism [14] . Additional indirect anti-microbial effects of NO

To investigate the effect of NO on Kp-induced pneumonia, mice were inoculated (by inhalation) with Kp (2,000 CFUs) and treated by breathing either NO in air or air alone (control) for 48 hours. Bacterial CFUs in lung, spleen and blood were measured 48h after inoculation. Mice treated with 160 or 200ppm NO had decreased numbers of bacteria in their lungs compared to mice breathing air alone (NO 160ppm vs air: 5.6 log10 CFU/g (4.9; 6.3) vs. 6.8 log10 CFU/g (6.4; 7.1) p=0.001; and NO 200ppm vs air: 4.5 log10 CFU/g (4.2; 5.2) vs. 6.7 log10 CFU/g (5.2; 7.9) p=0.029) ( Figure 1A , B).

Treatment with 80ppm NO did not have a significant effect on CFUs in lung tissue (NO 80ppm vs air: 5.8 log10 CFU/g (5.1; 6.7) vs. 6.6 log10 CFU/g (6.3; 7.3), p=0.102) ( Figure E1 ). NO had no effect on the number of CFUs in the spleen or blood of infected mice at any of the inhaled NO concentrations that were tested.

A potential adverse effect of inhaling high concentrations of NO is oxidation of the heme group of hemoglobin, producing methemoglobin. Methemoglobin does not carry oxygen, and increased methemoglobin levels limit the concentration of inhaled NO and the duration of treatment. The enzyme cytochrome b5 reductase, also known as methemoglobin reductase, catalyzes the reaction of MetHb to oxygenated hemoglobin (OxyHb) in red blood cells. To determine whether breathing high NO concentrations in air are associated with elevated levels of methemoglobinemia, we measured methemoglobin concentrations in blood after treatment with NO ( Figure 2A Administration of 300ppm NO for 12min or 30min produced a median methemoglobin level of 13% (10.6;13.8) and 41.3% (40.8; 51.7) (measured directly after treatment), respectively, suggesting that treating with NO at high concentration for the shorter duration might be safer (Figure 2A ). For mice treated with 200ppm NO for 24 hours or 300 ppm NO for 12 minutes, methemoglobin levels returned to baseline (less than 1%) 1.5 hours after discontinuation of NO treatment ( Figure 2B) Because treatment with NO 300ppm for 12min did not produce excessive methemoglobin levels, and because the level of methemoglobin returned to baseline 1.5h after ending NO inhalation, we tested the effect of a regimen of intermittent 300ppm NO on bacterial CFUs in mice infected with Kp. Six hours after inoculation, mice were treated with 300ppm NO for 12min every 3h for 48h. Compared to control mice breathing air alone, intermittent treatment with NO reduced bacterial CFU/g in lung tissue (6 log10 CFU/g (5.5; 6.6) vs. 0 log10 CFU/g (0; 4.4) p<0.001) ( Figure 3A ). However, intermittent, high dose NO had no effect on the number of CFUs in either the spleen or blood of infected mice ( Figure 3A ).

To investigate the potential effect of early treatment with NO on Kp-infection, mice were treated with intermittent NO (300ppm) or air alone, immediately after tracheal J o u r n a l P r e -p r o o f inoculation. As was observed in mice treated with intermittent NO 6 hours after infection, early NO inhalation was effective in eliminating bacterial CFUs from the lungs (intermittent NO 300ppm vs air: 0 log10 CFU/g (0; 0) vs. 6.5 log10 CFU/g (6.5 log10 CFU/g (5.6; 7.1), p=0.004) ( Figure 3B ). In contrast to mice treated 6 hours after infection, early treatment with intermittent NO at 300ppm also reduced bacterial CFUs in splenic tissue (NO vs air alone: 0 log10 CFU/g (0; 3.2) vs. 5.1 log10 CFU/g (2.5; 5.7), p=0.034) ( Figure 3B ). In addition, there was a trend towards reduction of bacteremia, with bacteremia occurring in 6 of 9 mice treated with air alone compared to 2 of 8 mice treated by breathing high dose, intermittent NO (chi-square test: p=0.086).

Taken together, the results show a dose dependent effect of NO on decreasing bacterial CFUs in the lung tissue of mice infected with Kp. Intermittent administration of NO allowed a higher concentration of NO to be used, without causing excessive methemoglobinemia, and was effective in reducing bacterial CFUs in the lung. Early treatment (immediately after bacterial inoculation) with high dose NO, eliminated viable bacteria in the lung and decreased the bacterial CFUs in the spleen.

Inoculation with Kp causes pneumonia in mice and leads to lung damage consisting of alveolar edema, infiltration of neutrophils and abscess formation. 

An in-vitro study was performed to investigate the effect of NO on multiple-drug, antibiotic resistant (MDR) Kp. The Kp strain used in these studies had known resistance to amoxicillin/clavulanic acid, meropenem, and cefepime, according to antibiotic sensitivity data from the vendor and verified by our institutional microbiology laboratory.

MDR Kp suspensions were incubated for 6 hours with NO from an NO donor (ranging from 1 µmol/L to 15 µmol/L [DETA NONOate: 0.167mg/mL to 2.5mg/mL]), sulpho NONOate, which releases nitrous oxide, but not NO (2.5mg/mL) or media alone, and CFUs were determined. Compared to MDR Kp grown in media alone, the addition of amoxicillin/clavulanic acid (32/16 µg/mL) had no effect on bacterial CFUs, nor did the J o u r n a l P r e -p r o o f addition of meropenem (2µg/mL). Cefepime (8µg/mL) has a small (but significant) effect on CFUs compared to controls ( Figure 7A ). The addition of NONOate to MDR Kp bacterial suspension caused a dose-dependent reduction in CFUs/mL. (Figure 7A ). NO at 7.5µmol/L was bactericidal, reducing CFUs by the end of the incubation period to lower CFU levels prior to the incubation period. The addition of sulpho NONOate were able to reduce CFUs of P. aeruginosa in rodent lung tissue [25, 26] . The relative insensitivity of Kp to low inhaled NO concentrations may be the result of organismdependent differences. Workman et al. suggested that species such as Kp require exposure to higher concentrations of NO to achieve complete bacteriostasis [27] . In this study, administration of high dose NO was achieved by limiting the duration of treatment with high dose NO to 12 minutes every three hours, thereby avoiding high levels of methemoglobinemia.

Treatment of mice with high dose intermittent NO, starting 6 hours after infection, decreased the number of CFUs in the lungs, but not the spleen. In contrast, initiating treatment immediately after infection decreased the number of CFUs in both the lung and spleen. The increased efficacy of early treatment may be of clinical importance for patients who experience an observed aspiration event or are at increased risk of aspiration because of intubation, stroke or dysphagia [28] .

The beneficial effect of NO inhalation on Kp CFUs in lung was associated with the absence of neutrophil infiltration in lung tissue and decreased MPO activity in lung extract. NO may exert a direct effect on inflammation, by decreasing the bacterial burden. NO may also produce an indirect effect on inflammation: previous investigators showed that NO inhibits the expression of many genes believed to be involved in inflammatory cascades, including nuclear factor-κB [29] , tumor necrosis factor-α [30] , and interleukin-1 [30] . In pigs challenged with intravenous lipopolysaccharide infusion, NO inhalation up-regulates glucocorticoid receptor expression, which is known to mediate anti-inflammatory responses [31] .

To investigate the underlying mechanism as to how NO exerts its bactericidal effect on Kp, we exposed Kp in-vitro to NO released from NO donor compounds and found that NO damages the bacterial cell wall of Kp in a dose dependent manner.

Deupree and colleagues observed a similar morphological effect of NO on the bacterial cell wall of P. aeruginosa and E. coli [32] . Degradation of the Kp cell wall, potentially mediated by nitrosation [11] , would be expected to increase cell wall permeability and may therefore facilitate entry of antibiotics into the organisms.

High dose NO had anti-microbial effects on both antibiotic sensitive and antibiotic resistant Kp in-vitro. Treatment with intermittent high dose NO may be especially beneficial in patients who develop frequent or chronic infections with antibiotic resistant organisms. Such patients include those with cystic fibrosis or chronic obstructive pulmonary disease. A phase I study involving eight cystic fibrosis patients with chronic pulmonary infections, intermittently breathing NO (160ppm in air), has already been completed and was shown to be safe [33] .

A potential limitation of the use of high concentrations of NO to treat infection is the adverse effects of increased levels of inhaled nitrogen dioxide (NO 2 ). Nitrogen dioxide reacts with water to form nitrous and nitric acid and can thereby damage epithelial cells [34] . In this study, administration of NO 300ppm to mice produced an inhaled NO 2 level that remained below 2ppm. The National Institute for Occupational Safety and Health's (NIOSH) recommended NO 2 exposure limit is 1ppm over a 15minute short-term interval, and the American Conference of Governmental Industrial

Hygienists has an threshold limit value of 3ppm for 8 hours [35] . Because the level of NO 2 increases with FiO 2 , the potential future use of NO to treat infections will require the J o u r n a l P r e -p r o o f use of potent NO 2 scavengers and careful monitoring of NO 2 levels. A second potential limitation of this study is that the results may not be generalizable to other organisms, including Enterococcus faecium, Staphylococcus aureus, and Acinetobacter baumanii, which are prone to develop antibiotic resistance [22] . Future studies should expand high dose nitric oxide treatment to a broad spectrum of bacteria to close this gap in our knowledge.

In summary, this study demonstrates that intermittent inhalation of 300ppm NO in air led to reduced Kp CFUs in lung tissue compared to air breathing controls. Early treatment with 300ppm NO decreased bacterial CFUs in both lung and splenic tissues. After a 6h incubation period, bacterial CFUs of multiple-drug resistant Kp increased and addition of amoxicillin/clavulanic acid 32/16µg/mL or meropenem 2µg/mL had no effect on the number of CFUs compared to bacteria grown in control media. Cefepime 8µg/mL has a small effect on Kp CFUs (7.4 log10 CFU/mL (7.2; 7.6), vs. 9.1 log10 CFU/mL

Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication

Antimicrobial reactive oxygen and nitrogen species: concepts and controversies

Inhaled nitric oxide for the adult respiratory distress syndrome

Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome

Inhaled nitric oxide in persistent pulmonary hypertension of the newborn

Nitric Oxide Story

Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S

Mitigation of the replication of SARS-CoV-2 by Nitric Oxide in Vitro

The chemical biology of nitric oxide: Implications in cellular signaling

Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens

Characterization of the Bactericidal Effects of Sodium Nitroprusside and Other Pentacyanonitrosyl Complexes on the Food Spoilage Bacterium Clostridium sporogenes

Inactivation of ribonucleotide reductase by nitric oxide

Nitric oxide-mediated regulation of ferroportin-1 controls macrophage iron homeostasis and immune function in Salmonella infection

Nitric oxide synthase in innate and adaptive immunity: an update

Endogenous Nitrated Nucleotide Is a Key Mediator of Autophagy and Innate Defense against Bacteria

Inhaled nitric oxide. A bronchodilator in mild asthmatics with methacholine-induced bronchospasm

Regulation of Mammalian Ciliary Beating

Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis

Hospital-Acquired Infections Due to Gram-Negative Bacteria

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis, The Lancet Infectious Diseases

Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE

Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS)

Neutrophils and immunity: challenges and opportunities

Effects of inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia

Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance

Relative susceptibility of airway organisms to antimicrobial nitric oxide

Microbiology of Severe Aspiration Pneumonia in Institutionalized Elderly

Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-κB and inflammation

Nitric Oxide Modulates Pro-and Anti-inflammatory Cytokines in Lipopolysaccharide-Activated Macrophages

Nitric oxide up-regulates the glucocorticoid receptor and blunts the inflammatory reaction in porcine endotoxin sepsis*

Morphological analysis of the antimicrobial action of nitric oxide on Gram-negative pathogens using atomic force microscopy

Gaseous nitric oxide to treat antibiotic and fungal lung infections in patients with cystic fibrosis: a phase I clinical study

Toxicity of nitrogen dioxide: an introduction

OSHA PEL Project -Nitrogen Dioxide | NIOSH | CDC

We thank Melis Anahtar, Qinfang Qian, John Branda and Anne Salle for determining and verifying antibiotic sensitivity of the used strain of bacteria.

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. RWC receives funding from UNITAID as a principal investigator in a multi-institutional study working to decentralize labs to diagnose and treat TB in low-resource settings.